Valye reports for unlimited access

Securitize Corp. is a company with limited publicly available information regarding its business model, sector, or industry classification. The latest SEC filing (10-Q) dated August 13, 2026, provides minimal financial data, primarily disclosing cash and cash equivalents of $1 million as of June 30, 2026. No revenue, profitability, or detailed operational metrics are disclosed. The company references risk factors in its Form S-1 registration statement but does not elaborate further in the recent quarterly filing. Recent public news coverage is limited to earnings call highlights from Q2 2026.

Archimedes Tech SPAC Partners II Co. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. It has not conducted operations or generated revenue and exists to identify and merge with a target business, primarily in the technology industry sectors of artificial intelligence, cloud services, and automotive technology. The company completed its IPO in February 2025, raising $230 million, with additional private placement proceeds. Funds raised are held in a trust account invested in low-risk government securities. The company has a 21-month window post-IPO to complete a business combination. The management team brings significant industry and SPAC experience, aiming to leverage their network and expertise to identify and support a suitable target business.

Richmond Mutual Bancorporation, Inc. is a Maryland-based bank holding company for First Bank Richmond, an Indiana-chartered commercial bank with multiple offices in Indiana and Ohio. The company offers a comprehensive suite of lending products including commercial real estate, construction, residential, consumer loans, and direct financing leases for equipment. It also provides trust and wealth management services. The company’s revenue primarily derives from net interest income, supplemented by service charges and fees. It operates under extensive regulatory oversight by the Federal Reserve Board, FDIC, and state regulators. The company’s leasing business relies on a network of brokers and third-party originators, with credit underwriting standards including minimum FICO scores. The company has adopted the CECL accounting model since 2023, affecting credit loss recognition. It maintains a strong focus on cybersecurity and regulatory compliance. The company pays quarterly dividends and has a shareholder base comprising institutional and retail investors.

Alliance Laundry Holdings Inc. specializes exclusively in commercial laundry systems, offering a comprehensive product range including washer extractors, topload and frontload washers, tumblers, small-chassis dryers, and combination washer-dryers. The company serves three core end markets: On-Premise Laundry (OPL), Vended laundromats and communal laundry operators, and Commercial In-Home customers seeking commercial-grade machines. It operates through two geographic segments: North America and International, with a global network of approximately 600 distributors and direct sales channels in select markets. The company emphasizes product quality, operational reliability, and total cost of ownership, enabling premium pricing and strong customer loyalty. Its manufacturing footprint spans six global facilities with advanced quality control and testing capabilities. The company also offers value-added services including equipment financing, digital monitoring platforms, and customer support programs. Its installed base of approximately eight million units supports recurring revenue from parts and services. The company reported $1.7 billion in net revenue for the twelve months ended December 31, 2025, with a net income margin of approximately 6%.

GlobalTech Corporation operates as a technology-focused company with activities spanning acquisitions, blockchain infrastructure development, AI innovation, and global talent acquisition. The company is headquartered in Reno, Nevada, and trades on the OTCQB Venture Market. It has a controlling shareholder owning over half of the outstanding shares. Recent strategic moves include acquiring a majority stake in Moda in Pelle and launching a Big Data & AI Center of Excellence in Pakistan. The company has also engaged strategic advisors and investor relations firms to support capital market activities. Financial disclosures indicate modest revenue and net income with liquidity challenges as of mid-2026.

Innventure, Inc. is a Delaware-based industrial growth conglomerate that specializes in founding, funding, and operating companies focused on commercializing disruptive and sustainable technology solutions. These technologies are typically sourced or licensed from multinational corporations (MNCs) or other technology innovators. The company employs a proprietary DownSelect process consisting of four phases to rigorously evaluate technology opportunities before launching new companies. This process includes opportunity screening, critical factor assessment, comprehensive quantification, and strategy formation. Innventure operates its portfolio companies through a Disruptive Conglomerate Model, providing shared services and maintaining controlling stakes to mitigate risks inherent in early-stage technology commercialization. The company currently controls AeroFlexx (sustainable liquid packaging), Accelsius (liquid cooling solutions for data centers), and Refinity (plastic waste conversion to chemicals). Innventure collaborates closely with MNCs, leveraging their proprietary market data, technology, and channel access to accelerate commercialization and early customer adoption. The business model emphasizes long-term ownership and operation rather than traditional venture capital exit strategies.

Park Dental Partners, Inc. is a dental resource organization (DRO) that provides comprehensive business and administrative support services to affiliated general and multi-specialty dental practices. Its network includes 214 dentists and approximately 990 supporting clinical staff across 86 locations in Minnesota, Wisconsin, and Arizona. The affiliated practices offer a range of dental services including general dentistry and specialties such as oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics. The company operates under long-term agreements with initial 30-year terms and automatic 5-year renewals. Revenues were $244.5 million in 2025. The company has grown through acquisitions (43 practices over 10 years) and opening new practices. Dentists hold majority ownership and have governance roles, providing clinical and operational input. The company was incorporated in 2023 by combining administrative resources of three established professional organizations. The business model focuses on providing dentists with operational support while preserving clinical autonomy and professional voice.

ENTREPRENEUR UNIVERSE BRIGHT GROUP operates as a holding company based in Nevada with its main business activities conducted through subsidiaries in Hong Kong and China. The primary operating subsidiary is located in Xi’an, China. The company expanded into the fintech sector by acquiring Heng Ying International Investment Limited, a Hong Kong money lender license holder, in February 2026. EUBG completed a reverse stock split in early 2026. The company’s revenue is generated mainly by its PRC subsidiary, which is subject to PRC regulatory and foreign exchange controls. EUBG maintains a cash management policy for its PRC subsidiary to safeguard monetary funds. The company’s financials as of mid-2026 show modest revenue with a small net loss and strong liquidity positions. EUBG faces risks from regulatory oversight in China, customer concentration, and potential changes in laws and policies affecting its business and stock value.

Aether Holdings, Inc. is a fintech company providing proprietary research analytics and AI-driven tools for equity and options traders via its SentimenTrader.com platform. It integrates advanced data collection, machine learning, and expert analysis to deliver market sentiment indicators and trading insights. The company has expanded its digital financial newsletter business through its subsidiary Alpha Edge Media, acquiring complementary digital asset content platforms to broaden its market coverage and subscriber base. It pursues a bitcoin treasury strategy as a core holding, though it had not acquired bitcoin as of the latest annual report. The company finances operations partly through secured promissory notes with restrictive covenants and faces ongoing litigation risks from a former director. Its financial position as of mid-2026 shows a strong current ratio but continued net losses.

CapsoVision, Inc develops and commercializes capsule endoscopy systems for the gastrointestinal tract, focusing on non-invasive diagnostic imaging. Its primary product, CapsoCam Plus, provides a 360-degree panoramic video of the small bowel and is FDA-cleared for adults and children aged 2 and above. The company integrates AI-assisted pathology detection technology to enhance diagnostic accuracy and efficiency. CapsoVision is advancing its pipeline with the CapsoCam Colon capsule, designed for colon visualization and polyp detection, incorporating AI and 3D sensing technology. The company sells primarily to gastroenterologists in the US and internationally through distributors. It holds over 140 patents and invests in R&D to improve its products and expand indications. The company has incurred net losses and faces liquidity and regulatory risks as it pursues FDA clearances and commercialization of new products [S1][S2].

Legence Corp. specializes in providing integrated engineering, installation, and maintenance services for mechanical, electrical, and plumbing systems in technically demanding buildings. The company targets high-growth industries including data centers, life sciences, healthcare, and education, generating significant revenue from these sectors. It operates through two segments: Engineering & Consulting, which offers design and project management services, and Installation & Maintenance, which handles fabrication, installation, and ongoing maintenance. The company maintains a broad geographic footprint across 46 U.S. states and the District of Columbia with 116 locations and approximately 7,000 employees. Its business model emphasizes long-term client relationships, a seller-doer sales approach, and a mix of fixed-price contracts with scope adjustments. Seasonal demand variations and competitive pressures are notable operational factors [S1].

Petros Pharmaceuticals, Inc. is focused on developing and licensing a proprietary integrated technology platform designed to facilitate the switch of prescription pharmaceutical products to over-the-counter (OTC) status. The platform includes a SaaS component to assist pharmaceutical companies in operationalizing and commercializing Rx-to-OTC switches, and a Software as a Medical Device (SaMD) component intended as a consumer interface to guide appropriate self-selection or deselection of OTC products. The company targets pharmaceutical innovative label owners and OTC commercial licensees interested in Rx-to-OTC switches. Petros does not engage in manufacturing or distribution but licenses its technology to partners who manage production and supply chains. The platform is in early development and aims to incorporate advanced features such as AI to enhance regulatory compliance and consumer safety. The company’s business model is based on licensing fees and customized virtual environments tailored to partners’ needs. Petros operates in a nascent market with limited direct competition in licensable ACNU Rx-to-OTC switch technologies. The company has an established industry network and participates in conferences to promote its technology and attract customers.

Charging Robotics Inc. specializes in wireless charging technology for electric vehicles, focusing on solutions for automatic parking systems (APS) where cable charging is impractical. The company’s technology uses resonance induction coils to wirelessly transfer electricity between a stationary transmitter installed in parking facilities and a receiver on APS plates that transport EVs. Charging Robotics has secured initial orders from multiple APS suppliers in Israel and has installed systems undergoing testing. The company also owns Revoltz Ltd., which produces micro-mobility electric vehicles for last-mile delivery, with commercial sales launched in Israel. Charging Robotics’ business model includes capital equipment sales, software-as-a-service, and electricity sales, targeting B2B customers such as public parking operators. The company is positioned in the growing EV market, addressing niche needs for automated and wireless charging solutions.

MaxCyte, Inc. operates as a commercial cell engineering company focused on enabling platform technologies for the discovery, development, and commercialization of next-generation cell therapeutics, including cell and gene therapies. The company has developed proprietary Flow Electroporation® technology, which facilitates the delivery of molecules such as DNA, mRNA, siRNA, and proteins into a wide variety of eukaryotic cells by temporarily increasing cell membrane permeability through an electric field. This technology underpins the ExPERT platform, which includes five instruments (DTx, ATx, STx, GTx, VLx) and a portfolio of proprietary disposables and consumables designed to support scalable cell engineering from research to cGMP manufacturing. MaxCyte's platform is used by leading biopharmaceutical companies, including a majority of the top 25 pharmaceutical companies by 2024 revenue, as well as academic and government research institutions. The company generates revenue from instrument sales, disposables, annual instrument license fees, and strategic partner license (SPL) agreements that include pre-commercial milestones and commercial sales-based payments. The company acquired SeQure Dx in 2025 to expand its assay and service offerings. MaxCyte maintains an FDA Master File referenced in over 75 clinical trials, supporting regulatory submissions for its customers. As of June 30, 2026, MaxCyte reported $7.27 million in revenue and a net loss of $8.87 million for Q2 2026, with a strong liquidity position including $15.0 million in cash and $90.6 million in short-term investments.

Cibus operates in the global seed market using proprietary gene editing technology to develop plant traits that improve crop productivity, sustainability, and adaptability. Its RTDS platform enables rapid and precise development of traits integrated into elite seed genetics. The company primarily licenses these traits to seed companies for royalties. Its initial commercial focus is on Rice herbicide tolerance traits targeting markets in the US, Latin America, and Asia. Cibus also develops sustainable ingredients such as bio-based fragrances. The company is consolidating operations and focusing resources on advancing its Rice programs while deferring non-partner-funded activities outside Rice. Regulatory progress in the US, Latin America, and Europe supports the commercial potential of its gene edited traits.

Boston Omaha Corporation operates as a publicly traded entity with Class A and Class B common stock listed on the NYSE under ticker BOC. The company is led by CEO Adam K. Peterson and governed by a board with diverse expertise in investment, real estate, technology, and financial services. As of mid-2026, Boston Omaha reported quarterly revenue of $22.2 million and a net loss of $1.61 million, with liquidity ratios indicating a current ratio of 2.05 and cash ratio of 0.31. The company is involved in regulatory-sensitive programs through its subsidiary FIF Utah, which has received grants and loans under the Rural Utilities Service ReConnect Program, requiring compliance with milestone and financial covenants. Additionally, Boston Omaha is pursuing the sale of its General Indemnity Group subsidiary, subject to regulatory approvals and closing conditions. Recent news coverage provides insights into insider transactions, market activity, and valuation considerations.

WhiteHawk Minerals Corp. is a company active in mineral acquisitions and operations, as evidenced by recent acquisitions totaling $111.8 million announced in the second quarter of 2026. The company reported revenues and net losses for the same period, indicating ongoing operational activities. It participates in industry conferences such as the EnerCom Denver Energy Investment Conference, suggesting engagement with the energy and minerals investment community. The company has initiated a quarterly dividend, indicating a strategic decision to return value to shareholders.

Embassy Bancorp, Inc. operates as a bank holding company with its banking subsidiary, Embassy Bank for the Lehigh Valley, serving primarily the Pennsylvania market, especially Lehigh and Northampton Counties. The company’s loan portfolio is concentrated in commercial real estate, commercial construction, and commercial loans, which are more susceptible to credit risk during economic downturns. Net interest income, the difference between interest earned on assets and interest paid on liabilities, is a primary source of profitability and is sensitive to changes in market interest rates. The company manages interest rate risk by controlling the mix of interest rate sensitive assets and liabilities but acknowledges that unexpected interest rate changes could adversely affect earnings. The company’s securities portfolio, primarily available-for-sale investments, impacts shareholders’ equity through unrealized gains and losses. Liquidity depends mainly on deposits, with additional funding from borrowings. The company faces strong competition from larger regional and national banks as well as non-bank financial service providers. Cybersecurity and information system risks are acknowledged, with policies and insurance in place to mitigate potential impacts. Embassy Bancorp does not engage in cryptocurrency transactions. Recent financial data as of June 30, 2026, includes net income of $4.123 million and EPS of $0.56 [S1][S2].

Idea Acquisition Corp. operates as a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. The company completed its initial public offering in February 2026, issuing units consisting of Class A ordinary shares and redeemable warrants. The proceeds from the IPO and related private placement are held in a trust account to be used for completing an initial business combination or returned to shareholders if no combination occurs within the specified timeframe. The company currently has no operating business or revenue, consistent with its SPAC status. Financial disclosures indicate a strong liquidity position as of mid-2026, with cash and current assets exceeding current liabilities by a significant margin. Risk disclosures reference the initial IPO prospectus with no material updates as of the latest quarterly report.

Horizon Space Acquisition I Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in June 2022. Its business model is to identify and complete a merger or acquisition with one or more target companies, using proceeds from its IPO and private placements held in a trust account. The company has not yet selected a target and has no operating revenue. It has extended its deadline to complete a business combination multiple times through shareholder approvals. The company terminated a previously announced business combination agreement in October 2025. It voluntarily delisted from Nasdaq and now trades on OTC markets. The company finances its operations through loans and securities sales, with limited cash and assets as of mid-2026. If unable to complete a business combination by the deadline, it plans to redeem public shares and liquidate.

Health In Tech, Inc. (HIT) is an AI-powered insurance technology platform company focused on the healthcare insurance industry. It offers a marketplace that enables insurance companies to list stop-loss policies for self-funded benefits plans, allowing licensed brokers to upload data, select plans, and obtain bindable quotes rapidly through AI-driven underwriting. HIT's platform simplifies and automates the traditionally complex and manual underwriting and sales processes, targeting small to large employers, especially those underserved in affordable health insurance. The company operates through three wholly owned subsidiaries: Stone Mountain Risk (SMR) for program management, International Captive Exchange (ICE) for underwriting and administrative services, and HI Card for healthcare management and claims processing. HIT's proprietary technology integrates AI and machine learning to reduce underwriting time to approximately two minutes in most cases. The company had a broad distribution network with hundreds of brokers and TPAs across 40 states as of 2025, serving nearly 800 business clients and over 22,000 employees. HIT reported significant revenue growth and maintains a focus on expanding its marketplace and product offerings while enhancing operational efficiency through AI and data analytics.

Roadzen Inc. develops and deploys AI-powered solutions for the insurance industry, focusing on underwriting, claims processing, and driver safety. Its flagship DrivebuddyAI platform is uniquely certified under India's AIS-184 standard for AI-based driver safety in commercial vehicles, supporting regulatory compliance and fleet safety. The company leverages a large proprietary dataset and over 300 AI models to improve insurance combined ratios and reduce accident rates. Roadzen operates globally, including a consolidated joint venture in China and recent expansion into European markets through acquisition. It maintains strategic partnerships, including with Anthropic for AI agent development. The company is publicly traded on Nasdaq as RDZN and is classified as an emerging growth company.

ChampionsGate Acquisition Corp is a special purpose acquisition company (SPAC) formed to effect a business combination with one or more target businesses. It has no operating history or revenue and is classified as a shell company. The company completed its IPO in May 2025, raising $74.75 million, which is held in a trust account invested in U.S. government securities. The company’s management seeks target businesses with strong management, growth potential, and defensible market positions. Public shareholders have redemption rights upon completion of the initial business combination. The company’s liquidity as of June 30, 2026, shows a current ratio of 0.2, indicating limited short-term financial flexibility.

Kraig Biocraft Laboratories, Inc. is a biotechnology company specializing in the development and production of recombinant spider silk through genetically engineered silkworms. The company focuses on scaling production of its BAM-1 Alpha spider silk hybrids and advancing its 'Project Atlas' to create new industrial and defense biomaterials. It operates as a smaller reporting company and has been recognized in scientific media such as National Geographic. The company reported a net loss and no revenue in its latest quarterly filing, with liquidity ratios indicating current liabilities exceed current assets as of June 30, 2026.

Lafayette Digital Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. It has no operations or revenue and is classified as a shell company. The company completed an IPO in January 2026, issuing units consisting of Class A ordinary shares and warrants, raising gross proceeds of $287.5 million. The proceeds are held in a trust account until the company completes an initial business combination or redeems public shares if unable to do so within 24 months. The company intends to focus on acquiring businesses in financial services and technology sectors, particularly those related to blockchain, digital assets, fintech, AI-enabled financial software, encryption, and cybersecurity. It leverages its management team's experience and network to source and evaluate acquisition targets. The company has established criteria for target selection, including market size, technology differentiation, financial profile, governance, and scalability. It plans to remain flexible in structuring its business combination transactions.

Off The Hook YS Inc. (OTH) is a holding company and the sole managing member of several subsidiaries focused on the marine industry, including yacht and boat sales, financing, servicing, and asset recovery. Founded in 2012, OTH has grown into a nationally recognized leader in the marine wholesale and retail market, generating over $119 million in annual sales and operating across eight locations with a team of 70 sales representatives. The company offers a diverse inventory of pre-owned and new boats, financing solutions through its Azure Funding subsidiary, comprehensive servicing via OTH Yacht Services, and asset recovery through Marine Asset Recovery. OTH leverages floorplan financing with a capacity of $60 million to support inventory acquisition and turnover. The company maintains strong partnerships with manufacturers, dealers, lenders, and marinas to support its integrated business model. Recent strategic acquisitions and partnerships aim to expand service capabilities and geographic reach [S1][S2].

TurnOnGreen, Inc. is a technology company specializing in custom power products and electric vehicle (EV) electrification infrastructure solutions. It operates through two subsidiaries: Digital Power Corporation (DPC), which focuses on highly engineered power conversion and control solutions for mission-critical applications across industries such as medical, military, and telecommunications; and TOG Technologies Inc. (TOGT), which markets and sells scalable EV charging products and comprehensive charging management software and network services. The company leverages proprietary core power technologies to deliver high-efficiency, high-density, and customizable power solutions. Its business model centers on providing advanced custom product design and manufacturing services to customers requiring high-quality, cost-effective power systems with rapid time to market. Recent financial disclosures indicate modest revenue growth and improved operating losses, though the company continues to report net losses and faces liquidity challenges. TurnOnGreen finances its operations through related party advances, equity sales, and convertible promissory notes. The company has secured multiple contracts and partnerships to deploy EV charging infrastructure and expand its defense market presence, demonstrating active business development efforts.

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company specializing in novel sublingual drug delivery technologies. Incorporated in 2025, Aspire focuses on developing sublingual formulations of known drugs, with its lead candidate being a high-dose aspirin product designed for rapid absorption and reduced gastrointestinal side effects. The company contracts third-party manufacturers for production and has completed positive clinical trials supporting an upcoming FDA NDA submission. Aspire also develops other sublingual products including melatonin, vitamins, erectile dysfunction medication, and caffeine supplements, with some products already launched commercially. The company maintains strong liquidity but operates at a net loss, reflecting its early-stage development status.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative solutions for severe pain relief that reduce the potential for opioid misuse, abuse, and overdose. The company’s proprietary platforms include the Trypsin Activated Abuse Protection (TAAP) technology, which releases active drugs only under specific physiological conditions to deter abuse, and the Multi-Pill Abuse Resistant (MPAR®) technology, which combines TAAP prodrugs with a trypsin inhibitor to provide overdose protection. Its lead product candidate, PF614, is a TAAP oxycodone prodrug designed to resist oral and non-oral abuse, currently in a pivotal Phase 3 trial. PF614-MPAR, a combination of PF614 and nafamostat, has received FDA Breakthrough Therapy designation and is undergoing clinical evaluation. Ensysce relies on contract manufacturing organizations for production and has no approved commercial products or revenues to date. The company has incurred significant losses since inception and faces liquidity challenges as of mid-2026.

Viewbix Inc. is a provider of digital advertising platforms, generating revenue primarily through the sale of these platforms. The company relies heavily on a major international search engine customer, which accounted for approximately 81% of revenues for its digital advertising business unit in 2025. This relationship is governed by an exclusive cooperation agreement with automatic renewal provisions. Viewbix depends on a network of supply sources including direct publishers and advertising exchanges to deliver advertising inventory. The company has expanded its business through acquisitions of Quantum Israel (Quantum X Labs), focusing on quantum computing algorithms, and Metagramm, specializing in advanced writing assistance tools. These acquisitions introduce new product lines and revenue models distinct from Viewbix's traditional platforms. Financially, the company reported $293,000 in revenue and $2.485 million in net income for Q2 2026, with cash and equivalents of $2.435 million as of June 30, 2026. However, recurring losses and negative operating cash flows have led to substantial doubt about its ability to continue as a going concern. The company operates primarily in Israel, exposing it to geopolitical and regional risks. Viewbix faces competitive challenges from major technology firms and must navigate evolving digital advertising regulations and technological changes.

Fortress Biotech, Inc. operates as a biopharmaceutical company with a portfolio of subsidiaries engaged in drug development, commercialization, and specialty pharmaceutical activities. The company’s business model includes advancing clinical-stage assets, obtaining regulatory approvals, and monetizing assets such as Priority Review Vouchers (PRVs). Fortress maintains financing arrangements including a senior secured credit facility with Oaktree and utilizes equity offerings and warrant exercises to support operations. The company’s subsidiaries have achieved regulatory milestones, including FDA approval of ZYCUBO for Menkes disease, and have engaged in asset sales such as the PRV sale by Cyprium Therapeutics. Fortress reports liquidity metrics indicating a strong cash position and current ratio as of mid-2026.

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders. The company’s lead product candidate, CAD-1005, is a first-in-class selective 12-lipoxygenase (12-LOX) inhibitor targeting heparin-induced thrombocytopenia (HIT), a serious immune-mediated thrombotic condition. CAD-1005 has received orphan drug and Fast Track designations from the FDA and orphan designation from the EMA. Clinical development includes completed Phase 1 trials and a Phase 2 blinded, placebo-controlled pilot study. The Phase 2 study did not meet its primary endpoint but showed a reduction in thrombotic events in the treatment group. The company plans a Phase 3 pivotal trial following FDA End-of-Phase 2 discussions. The broader pipeline includes tecarfarin, an oral vitamin K antagonist designed for patients with complex anticoagulation needs such as those with kidney dysfunction or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor for acute care settings. Manufacturing is outsourced to third-party contract development and manufacturing organizations (CDMOs). The company has no long-term supply or commercialization agreements in place. Competition includes existing anticoagulants such as warfarin and direct oral anticoagulants. Financially, Cadrenal has incurred significant losses and faces liquidity challenges, with a strategic pivot toward partnerships and out-licensing to support development and operations.

BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies primarily for neuropsychiatric disorders and immuno-oncology. The company is in clinical development stages with no reported revenue as of the latest data. It is advancing clinical trials for its lead product candidates, including BXCL501, targeting acute stress reactions and agitation in psychiatric conditions. The company has reported ongoing net losses and is investing in regulatory filings to expand drug indications and usage settings.

TAO Synergies Inc. is a publicly traded company on Nasdaq under the ticker TAOX, having undergone a rebranding in June 2025. The company’s detailed business model and industry classification are not explicitly disclosed in the available data. Financial disclosures indicate the company operates with significant liquidity but is currently reporting net losses and negative earnings per share. The company has issued common stock for investor relations services and maintains multiple convertible preferred stock series and warrants. Recent leadership changes at Synaptogenix, a related entity, suggest strategic adjustments within the broader corporate structure.

Capstone Companies, Inc. was historically engaged in consumer product design and licensing, notably the Connected Chef kitchen tablet. The company ceased promotion of its LED Lighting product line due to market maturity and declining revenues. Attempts to commercialize the Connected Chef product through licensing ended unsuccessfully in late 2025. Since 2024, Capstone has focused on developing a new business line in the health, fitness, and social activities (HFS) industry, leveraging the expertise of its CEO, Alexander Jacobs, who has experience in this sector through Coppermine Ventures LLC. Despite these efforts, the company has not acquired or developed any HFS operations as of mid-2026. Financially, Capstone faces significant liquidity constraints, with current liabilities exceeding current assets and ongoing net losses. The company depends on unsecured promissory notes from Coppermine and eBliss for working capital. Business development efforts in the HFS sector are currently suspended due to a 'no shop' provision in the eBliss Note. The company’s future operations depend on securing additional funding, with substantial doubt expressed about its ability to continue as a going concern.

Miluna Acquisition Corp operates as a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business model centers on identifying and completing an initial business combination with one or more target companies across various industries and geographies, excluding the PRC. The company completed its IPO in October 2025, raising gross proceeds of $69 million, which are held in a trust account invested in U.S. government securities. The management team brings significant experience in mergers and acquisitions and aims to leverage its network to source attractive acquisition opportunities. The company announced a planned merger with CADV Ventures S.A. to become a publicly listed entity. The company has liquidity with a current ratio of 4.26 as of June 30, 2026, and reported net income for the quarter ended June 30, 2026.